Does Auvelity Lower the Seizure Threshold?
Yes, Auvelity lowers the seizure threshold due to its bupropion component, which is a well-established risk that requires careful patient selection and monitoring.
Mechanism and Evidence
The seizure risk with Auvelity is directly attributable to bupropion, one of its two active components. Bupropion is known to reduce the seizure threshold in a dose-dependent manner 1. The FDA drug label explicitly warns that "AUVELITY contains bupropion which can cause seizure" and states that co-administration with other drugs that lower seizure threshold may increase this risk 1.
Clinical Contraindications and Precautions
Auvelity should be avoided entirely in patients with seizure disorders 2. Multiple obesity management guidelines consistently identify seizure disorder as an absolute contraindication when using naltrexone-bupropion ER (which contains the same bupropion component) 2.
Use extreme caution in patients with clinical factors that may increase seizure risk, including 2:
- History of prior seizures
- Brain metastases or structural brain lesions
- Stroke history
- Conditions that lower seizure threshold
The smoking cessation guidelines specifically note that bupropion is contraindicated in patients with brain metastases due to seizure risk 2.
Management Algorithm
If a patient experiences a seizure while on Auvelity:
- Discontinue AUVELITY immediately
- Do not restart treatment 1
When prescribing Auvelity, screen for:
- Personal history of seizures or epilepsy
- Structural brain abnormalities
- Concurrent medications that lower seizure threshold
- History of head trauma
- Alcohol or benzodiazepine withdrawal states 2
Quantified Risk
The seizure risk with bupropion monotherapy has been documented at approximately 0.1% in clinical trials for smoking cessation 2. However, this risk increases with:
- Higher doses
- Rapid dose escalation
- Concurrent use of other seizure threshold-lowering medications 1
Drug Interactions Amplifying Risk
Exercise particular caution when combining Auvelity with other agents that lower seizure threshold 1. The FDA label specifically warns about co-administration with such drugs and recommends using caution in these scenarios 1.
Clinical Context
While Alzheimer's disease management guidelines note that bupropion "should not be used in agitated patients and those with seizure disorders" 2, this principle applies universally across all bupropion-containing products, including Auvelity.
The seizure-lowering effect is an inherent pharmacological property of bupropion and cannot be mitigated through dose adjustment alone—patient selection is paramount 2.